Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Aim: The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP‐lowering effects of GLP1‐RAs. Methods: A comprehensive database search for placebo‐controlled randomized controlled trials on GLP‐1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with a mean difference (MD) in mmHg and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic BP (SBP) and diastolic BP. Subgroup analyses and meta‐regressions were done to account for covariates. Results: Compared with placebo, GLP‐1RAs modestly reduced SBP [semaglutide: MD −3.40 (95% CI −4.22 to −2.59, p < .001); liraglutide: MD −2.61 (95% CI −3.48 to −1.74, p < .001); dulaglutide: MD −1.46 (95% CI −2.20 to −0.72, p < .001); and exenatide: MD −3.36 (95% CI −3.63 to −3.10, p < .001)]. This benefit consistently increased with longer treatment durations. Diastolic BP reduction was only significant in the exenatide group [MD −0.94 (95% CI −1.78 to −0.1), p = .03]. Among semaglutide cohorts, mean changes in glycated haemoglobin and mean changes in body mass index were directly associated with SBP reduction. Conclusion: Patients on GLP‐1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that BP‐lowering is an indirect effect of GLP‐1RA and unlikely to be responsible for the benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“63 – RCTs. 18,20,21,27,32,46,53,57,62,67,72,75 Thirty-eight RCTs 15,17,18,21 – 23, 25,28,31,32,34,36 – 38,40,42,44 – 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used…”
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“…– 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used seated BP, Gullaksen et al. 71 used supine BP, Wadden et al. 65 used standing BP, Dushay et al. 72 did not mention the posture of the patient…”
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“92 Weight loss is a notable effect of GLP-1RAs, as shown in multiple RCTs and meta-analyses 93,94 and weight loss decreases SBP by 5 mmHg among patients with hypertension and 2-3 mmHg among patients with normotension, with a dose-response relationship of about 1 mmHg per kg of weight loss.”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 3×
“…– 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used seated BP, Gullaksen et al. 71 used supine BP, Wadden et al. 65 used standing BP, Dushay et al. 72 did not…”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412 · cited 2×
“…– RCTs. 18,20,21,27,32,46,53,57,62,67,72,75 Thirty-eight RCTs 15,17,18,21 – 23, 25,28,31,32,34,36 – 38,40,42,44 – 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used…”
InfluentialSideri, S., Papageorgiou, S. N., & Eliades, T. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.01.003 · Cited by 388
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351 · cited 2×
“63 – RCTs. 18,20,21,27,32,46,53,57,62,67,72,75 Thirty-eight RCTs 15,17,18,21 – 23, 25,28,31,32,34,36 – 38,40,42,44 – 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used…”
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · cited 1×
“Of the GLP-RAs included in our meta-analysis, we found that only exenatide reduced DBP with statistical significance, albeit clinically modest with a mean difference of (cid:1) 0.94 mmHg (95% CI (cid:1) 1.78 to (cid:1) 0.10), p = .03), driven mainly by the Moretto et al. 96 and Buse et al. trials.”
InfluentialKadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330 · cited 3×
“…reduction in SBP. 22,28,36,71 On the other hand, SBP reduction among RCTs that administered semaglutide for >26 weeks varied, as some trials 34,43,66 failed to show significant SBP reduction but most other trials with a duration >26 weeks 16,17,19,26,29 – 31 were able to show this treatment effect.”
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 2×
“7,98 To our knowledge, this is the first meta-analysis and meta-regression to comprehensively report on the efficacy of GLP-1RAs in reducing BP.”
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296 · cited 5×
“Two large RCTs 35,60 were able to successfully show this modest reduction in SBP.”
InfluentialKlausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262 · cited 1×
“63 – RCTs. 18,20,21,27,32,46,53,57,62,67,72,75 Thirty-eight RCTs 15,17,18,21 – 23, 25,28,31,32,34,36 – 38,40,42,44 – 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used…”
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · cited 1×
“92 Weight loss is a notable effect of GLP-1RAs, as shown in multiple RCTs and meta-analyses 93,94 and weight loss decreases SBP by 5 mmHg among patients with hypertension and 2-3 mmHg among patients with normotension, with a dose-response relationship of about 1 mmHg per kg of weight loss.”
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Sandsdal, R. M., Juhl, C. R., Jensen, S. B. K., Lundgren, J. R., Janus, C., Blond, M. B., Rosenkilde, M., Bogh, A. F., Gliemann, L., Jensen, J.-E. B., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01765-z · Cited by 195
Mok, J., Adeleke, M. O., Brown, A., Magee, C. G., Firman, C., Makahamadze, C., Jassil, F. C., Marvasti, P., Carnemolla, A., Devalia, K., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.2930 · Cited by 178
Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Maselli, D., Atieh, J., Clark, M. M., Eckert, D., Taylor, A., Carlson, P., Burton, D. D., Busciglio, I., Harmsen, W. S., Vella, A., et al. (2022) · Obesity · doi:10.1002/oby.23481 · Cited by 136
McGuire, D. K., Busui, R. P., Deanfield, J., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N., Engelmann, M. D. M., Hovingh, G. K., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15058 · Cited by 131 · cited 10×
“92 Weight loss is a notable effect of GLP-1RAs, as shown in multiple RCTs and meta-analyses 93,94 and weight loss decreases SBP by 5 mmHg among patients with hypertension and 2-3 mmHg among patients with normotension, with a dose-response relationship of about 1 mmHg per kg of weight loss.”
InfluentialMatikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · cited 2×
“…18,20,21,27,32,46,53,57,62,67,72,75 Thirty-eight RCTs 15,17,18,21 – 23, 25,28,31,32,34,36 – 38,40,42,44 – 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used seated BP,…”
Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22359 · Cited by 116 · cited 2×
“63 – RCTs. 18,20,21,27,32,46,53,57,62,67,72,75 Thirty-eight RCTs 15,17,18,21 – 23, 25,28,31,32,34,36 – 38,40,42,44 – 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used seated BP, Gullaksen…”
Kuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13167 · Cited by 98
Lingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care · doi:10.2337/dc17-2381 · Cited by 81 · cited 3×
“Two large RCTs 35,60 were able to successfully show this modest reduction in SBP.”
Whicher, C. A., Price, H. C., Phiri, P., Rathod, S., Barnard‐Kelly, K., Ngianga, K., Thorne, K., Asher, C., Peveler, R. C., McCarthy, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14334 · Cited by 77
Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0507 · Cited by 54 · cited 1×
“…– 46,48,50,52,54,55,57 – 59,62,63,67,69 – 71,75,78 were done exclusively among patients with DM. 23, 25 – 36 ,38, 40 – 22 RCTs 15 – 20,23,25 – 28,34,37,41,45,48,51,54,55,64,66,73 used seated BP, Gullaksen et al. 71 used supine BP, Wadden et al. 65 used standing BP, Dushay et al. 72 did not mention…”
Jalleh, R. J., Jones, K. L., Nauck, M., & Horowitz, M. (2023) · Annals of Internal Medicine · doi:10.7326/m23-2019 · Cited by 18
Cited by
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“These contradictory findings suggest that GLP-1 RAs’ effects on DBP may vary across studies [90, 91].”
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
Metadata
- Authors
- Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara‐Breitinger, K. M., Gulati, M., & Bakris, G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2024-03-20
- Volume
- 26
- Issue
- 6
- Pages
- 2209-2228
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4393008098
- Cited by
- 57
- References
- 51
- FWCI
- 15.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.